Skip to content

Murivenna anal infiltration for chronic anal fissure

Efficacy and safety of Murivenna anal infiltration compared to Diltiazem topical application in chronic anal fissure: A prospective randomized open-label clinical trial - CAF

Status
Active, not recruiting
Phases
Phase 4
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2023/09/057330
Enrollment
66
Registered
2023-09-06
Start date
Unknown
Completion date
Unknown
Last updated
2025-11-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: K601- Chronic anal fissure

Interventions

None listed

Sponsors

Central Council for Research in Ayurvedic Sciences
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: a. Patients of either sex with chronic anal fissure greater than 6 weeks of duration b. Patients between the age group of 16 - 65 years c. Patients capable of and freely willing to provide written informed consent prior to participating in the study and comply with the study protocol requirements. d. Patients willing to discontinue or avoid nonprescription and prescription medicine (apart from conservative care such as diet, adequate fluid, and sitz baths) for the treatment of Chronic Anal Fissure for the duration of the study.

Exclusion criteria

Exclusion criteria: a. Patients with other co-morbidities like uncontrolled Diabetes mellitus, anemia, malnourishment caused by systemic diseases, fistula in ano, haemorrhoids, perianal abscess, clinically evident fecal incontinence & anal stenosis/fibrosis, inflammatory bowel disease, tuberculous ulcer, malignancies and HIV b. Patients with uncontrolled hypertension, clinically significant renal disease, hepatic disease and cardiovascular disease, psychological diseases (anxiety, depression etc.), active substance abuse and patients on medications hampering wound healing. c. Fissure associated with abscess, Drug induced fissures or fissure resulting from external trauma d. Fissures located at lateral locations and multiple fissures e. Patients using oral calcium channel blockers f. Known sensitivity to intervention drug or calcium channel blockers g. Patients with frequent h/o headaches and who are receiving any steroids, NSAIDs, etc., either for fissure or any unrelated disease condition. h. Pregnant and lactating women i. Patients who have been using either of the trial interventions within 30 days of randomization of the trial.

Design outcomes

Primary

MeasureTime frame
Complete healing of the anal fissureTimepoint: 4 weeks

Secondary

MeasureTime frame
1. Complete healing of the anal fissure after 7 days & 14 days. 2. Pain during defecation 3. Time to cessation of bleeding 4. Recurrence 5. Adverse eventsTimepoint: 1. 8th & 15th day 2.3. - 8th, 15th , 22nd & 30th day 4. 5 months 5. 30 days

Countries

India

Contacts

Public ContactDr Pratap Shankar K M

National Ayurveda Research Institute for Panchakarma

kmpvarma@gmail.com9744824014

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 5, 2026